TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00799240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A: Pemetrexed Cisplatin
Description: Pemetrexed: 500mg/m2 IV on day 1 and Cisplatin: 75 mg/m2 IV on day 1 every 21 days x 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B Pemetrexed, Cisplatin and MK-0646
Description: Pemetrexed 500 mg/m2 IV on Day 1 and Cisplatin 75 mg/m2 IV on Day 1 every 21 days for 6 cycles in combination with MK-0646 will be given IV, 10 mg/KG, Days 1, 8 and 15 weekly.
Study: NCT04423029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT04391894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECF843
Description: Topical ocular eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECF843
Description: Topical ocular eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECF843
Description: Topical ocular eye drop

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECF843 vehicle
Description: Topical ocular eye drop

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECF843 vehicle
Description: Topical ocular eye drop

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECF843 vehicle
Description: Topical ocular eye drop

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ECF843 vehicle
Description: Topical ocular eye drop

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ECF843 vehicle
Description: Topical ocular eye drop
Study: NCT02584530

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance for PICC line placement
Description: Apply ultrasound guidance for PICC line placement and positioning in newborns
Study: NCT00812006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate
Description: rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate
Description: rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate
Description: rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack
Study: NCT04300517

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Three sachet of protein supplement to be mixed in with water used daily
Description: Three sachet of protein supplement to be mixed in with water used daily
Study: NCT01141855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Champix
Description: Standard MIMS dosage (including period of titration) will be used. 0.5mg daily for 3 days 0.5mg b.d. for 4 days~1mb b.d. for 70 days (full course 3 months)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselling alone
Description: Quit SA 5A counselling over the phone. Maximum 8 calls over a 3 month period
Study: NCT04460508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated rhG-CSF
Description: Pegylated rhG-CSF:6mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF
Description: rhG-CSF:5ug/kg/d
Study: NCT02553447

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study: NCT04314648

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Substance Use Treatment and Recovery Team (START)
Description: Embedding of a collaborative care team, called the Substance Use Treatment and Recovery Team (START), for inpatients with OAUDs within an existing hospital consultation liaison psychiatry service.
Study: NCT00003593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV
Study: NCT01886196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drug (Ibuprofen)
Description: 400mg of ibuprofen administered after exercise training session 3 days per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drug (Ibuprofen)
Description: 400mg of ibuprofen administered after exercise training session 3 days per week

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: placebo designed to mimic experimental drug (ibuprofen)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo designed to mimic experimental drug (ibuprofen)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo designed to mimic experimental drug (ibuprofen)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: 3 sets of 8-12 repetitions of resistance exercise (full body with a focus on the distal radius) completed 3 days/week under supervision in the research gym

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance exercise
Description: 3 sets of 8-12 repetitions of resistance exercise (full body with a focus on the distal radius) completed 3 days/week under supervision in the research gym

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Flexibility training
Description: 3 days of full body stretching program (approximately 1 hour) to be performed at participants home unsupervised
Study: NCT03859765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HCT Symptoms and Steps
Description: HCT Symptoms and Steps will provide patients with cognitive behavioral coping skills training and activity coaching sessions to enhance their ability to manage symptoms that interfere with activity.
Study: NCT02929524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
Study: NCT03832101

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MATB
Description: MATB has two multitasking tasks and two attention tasks. The two multitasking tasks evaluates performance on multiple cognitively demanding assignments in both the auditory and visual domains. The two attention tasks measures performance in sustained and selective attention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MATB
Description: MATB has two multitasking tasks and two attention tasks. The two multitasking tasks evaluates performance on multiple cognitively demanding assignments in both the auditory and visual domains. The two attention tasks measures performance in sustained and selective attention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MATB
Description: MATB has two multitasking tasks and two attention tasks. The two multitasking tasks evaluates performance on multiple cognitively demanding assignments in both the auditory and visual domains. The two attention tasks measures performance in sustained and selective attention
Study: NCT01239134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRX518
Description: Humanized, Fc disabled, anti-human GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody
Study: NCT01085123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapimelt
Description: oral tablet , 2.5 and 5 mg, single dose. 10 mg (2x5 mg) visit 3, 5 mg visit 4, 2.5 mg visit 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]AZ10419369
Description: solution for iv injection. Will be injected within 2 to 5 hours after administration of ZOMIG® Rapimelt
Study: NCT00003593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study: NCT04300517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Three sachet of protein supplement to be mixed in with water used daily
Description: Three sachet of protein supplement to be mixed in with water used daily
Study: NCT03030495

Intervention type: DEVICE
Intervention: Comprehensive physiologic evaluation
Description: Comprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance

Intervention type: DEVICE
Intervention: Comprehensive physiologic evaluation
Description: Comprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance

Intervention type: DEVICE
Intervention: Intravascular imaging devices
Description: Intravascular ultrasound or optical coherence tomography
Study: NCT00003593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given IV
Study: NCT03030495

Intervention type: DEVICE
Intervention: Intravascular imaging devices
Description: Intravascular ultrasound or optical coherence tomography
Study: NCT01796990

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ACT
Description: The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. The group size is about 8-10 members per one group. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: REF
Description: The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REF
Description: The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
Study: NCT02511093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TBC intervention
Description: A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:~* BP measurements;~* an educational and counselling intervention on patient adherence;~* an educational and counselling intervention on lifestyle (physical activity and diet) Physicians adjust antihypertensive medications based on nurse and pharmacist feedback.
Study: NCT02497144

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NMES Group
Description: Neuromuscular electrical stimulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Breathing exercises
Study: NCT04381949

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positive pressure extubation
Description: Two arms:~the first with classic extubation with disconnection of the ventilator and the second with an extubation without disconnection of the respiratory positive pressure
Study: NCT02246075

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EVP-6124
Study: NCT01506167

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab was administered as part of standard first-line treatment

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab was administered as part of standard first-line treatment
Study: NCT02246075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124
Study: NCT02502461

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cuff palpation
Description: Inflated endotracheal tube cuff palpated through anterior extra-thoracic trachea while tube is gently moved to place the cuff midway between cricoid and sternal notch.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: cuff palpation
Description: Inflated endotracheal tube cuff palpated through anterior extra-thoracic trachea while tube is gently moved to place the cuff midway between cricoid and sternal notch.
Study: NCT01672333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOX
Description: oxaliplatin 100mg/m2 IV over 2 hours at 1st day docetaxel 50 mg/m2 IV over 1 hour at 1st day capecitabine 625 mg/m2 PO for 14 days
Study: NCT01401790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telehomecare (Intelligent Distance Patient Monitoring)
Description: Randomized patients were to be taugth and to use for 3 months a telehomecare program designed for~* Automatic download of blood glucose levels~* Automatic alerts indicating hypoglycemias, hyperglycemias and ketones to the medical team~* Changes in treatment plan by the diabetes professionals~* E mail exchanges between families and health care professionals~* Reinforcement of teaching program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard education and follow up at diabetes clinic
Description: Patients allocated to the control branch receive standard diabetes teaching and care.
Study: NCT04011722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portico™ NG (Navitor) Valve and FlexNav™ Delivery System
Description: Subjects will undergo transcatheter aortic valve implantation (TAVI) with the new generation Portico NG (Navitor) valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System
Description: Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor Titan valve and large FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
Study: NCT05022446

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT03939715

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DermaPure®
Description: Surgical intervention using DermaPure®

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: native tissue
Description: Surgical intervention using native tissue
Study: NCT01349777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregrel®
Description: Pregrel® 75mg daily for 12 months
Study: NCT03516032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercises
Study: NCT03524963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostan CR Tab.
Description: Cilostan CR Tab. 200mg once a day for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostan CR Tab.
Description: Cilostan CR Tab. 200mg once a day for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pletaal SR Cap.
Description: Pletaal SR Cap. 200mg once a day for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pletaal SR Cap.
Description: Pletaal SR Cap. 200mg once a day for 5 days
Study: NCT00771706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor
Description: The PPI arm will consist of a two week course of PPI at a dose 1mg/kg/dose twice daily (minimum dose: 7.5 mg BID; maximum dose: 30 mg BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
Study: NCT01728558

Intervention type: OTHER
Group type: OTHER
Intervention: Early goal Directed Sedation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care sedation
Study: NCT01231542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 is an experimental drug for the treatment of HIV. GSK1349572 is in the integrase inhibitor class. It is not yet approved by the FDA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 is an experimental drug for the treatment of HIV. GSK1349572 is in the integrase inhibitor class. It is not yet approved by the FDA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin is approved by the FDA for the treatment of tuberculosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Rifabutin is approved by the FDA for the treatment of tuberculosis.
Study: NCT00607269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher-Based Reinforcement Therapy
Description: Participants were randomized into either the CM or control condition. Both conditions earned points for attendance and participation (max 364 points).~Participants in the CM condition also earned points for targeted health-promoting behaviors and for drug/alcohol abstinence. CM points for targeted health-promoting behaviors were not limited. Points for abstaining from substance use were awarded based on a Level 1 (recent abstinence for amphetamine, methamphetamine, PCP, and cocaine metabolites, as well as blood alcohol \<0.05) urine sample.
Study: NCT00098748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Therapy (OBT)
Description: OBT (3-6 drugs based on treatment history and resistance testing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc (UK-427,857)
Description: maraviroc (UK-427,857) 150 mg taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Therapy (OBT)
Description: OBT (3-6 drugs based on treatment history and resistance testing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc (UK-427,857)
Description: maraviroc (UK-427,857) 150 mg taken twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Therapy (OBT)
Description: OBT (3-6 drugs based on treatment history and resistance testing)
Study: NCT02975479

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALK Diluent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALK Alutard SQ 5-grasses or ALK Alutard Birch
Description: Depot formulation of relevant allergen adsorbed to aluminium hydroxide in a suspension.
Study: NCT03305081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD, copper IUD, etonorgestrel implant
Description: Long-acting reversible contraception

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel IUD, copper IUD, etonorgestrel implant
Description: Long-acting reversible contraception
Study: NCT03955250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile After-Care Support (MACS) app
Description: The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile app attention control
Description: The control app provides ecological momentary assessment and psychoeducation about illness.
Study: NCT01349777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix®
Description: Plavix® 75mg daily for 12 months
Study: NCT02969265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCV-116CCB
Description: TCV-116CCB Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine Placebo
Description: Amlodipine placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine Placebo
Description: Amlodipine placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCV-116CCB Placebo
Description: TCV-116CCB 8/5 mg placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCV-116CCB Placebo
Description: TCV-116CCB 8/5 mg placebo-matching tablets